期刊文献+

氯沙坦对老年高血压患者肾功能改善的临床观察 被引量:3

The clinical investigation of Losartan to improvement of renal function in elderly hypertensive patients
暂未订购
导出
摘要 目的 观察氯沙坦 (科素亚 )对老年高血压患者肾脏血流动力学及肾功能的影响。方法 选择 43例老年高血压患者 ,给予氯沙坦 50~ 1 0 0 mg/日 ,治疗 1 2~ 1 7个月 ,应用彩色多普勒超声 ,分别测定治疗前后肾血流动力学及肾结构的变化 ,检测血浆血管紧张素 (Ang- ) ,血、尿 β2微球蛋白 (β2 - MG)水平。结果 氯沙坦治疗后患者血压明显下降 (P<0 .0 0 1 ) ,肾血流阻力指数 (RI)、搏动指数 (PI)、Vsmax/ Vdmin比值双肾均显著降低 (P<0 .0 1 ) ,治疗后管壁厚度明显变薄 ,治疗前后肾动脉管壁厚度有显著差异 (P<0 .0 1 ) ,动脉内径增宽 (P<0 .0 5)。血 β2 - MG浓度降低、尿 β2 -MG排泄量明显减少 (P<0 .0 1 ) ,血浆 Ang- 水平有增加趋势 (P>0 .0 5)。结论 氯沙坦有降血压、降低肾动脉血管阻力 ,增加肾血流量 ,改善肾血管结构 ,降低血β2 - MG,降低尿β2 - MG排泻 ,从而改善肾脏功能。 Objective To observe the clinical effect of Losartan on renal hemodynamics and function in elderly hypertensive patients.Methods Forty-three elderly hypertensive patients were treated with Losartan, 50-100 mg/d for twelve to seventeen months. The variation of renal hemodynamics and structure, plasma AngⅡ, blood and urine microglobulin of β 2-MG before and after treatment,applying the colour Doppler Ultrasonography and kits,were determined.Results After treatment the pationts' blood pressure have reduced effectively (P<0.001). RI,PI and the Vsmax/Vdmin ratio were markedly decreased in left (P<0.01) and right (P<0.05)kidney after treatment. Thickness of renal arterial wall was significantly decreased (P<0.01), the renal arterial diameter were obviously increased (P<0.05), β 2-MG in blood and urine were obviously decreased after administration. The level of plasma AngⅡ has a slightly increased trend(P>0.05).Conclusions Losartan was effective in reducing hypertension, it also could decrease the renal arterial vessel resistance and increase the renal blood flow and improve the renal vessel structure, decrease the concentration of β 2-MG in blood and urine,and then improved renal function.
出处 《中国老年学杂志》 CAS CSCD 北大核心 2003年第11期720-721,共2页 Chinese Journal of Gerontology
关键词 氯沙坦 老年人 高血压 肾功能 临床观察 血流动力学 彩色多普勒超声 Losartan Hypertensive Doppler Ultrasonography Renal function
  • 相关文献

参考文献6

  • 1Coldberg MR, Bradstreet TE, Mc Williams EJ, et al. Biochemical effects of Losartan, a nonpeptide angiotensin Ⅱ receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients, [J]. Hypertension, 1995 ; 25 (1) : 37-46,.
  • 2Birkenhager WH, del-Leeuw PW. Non-pep-tide angiotensin type I receptor antagonists in the treatment of hypertension [J].Hypertension, 1999 ; 17(7) :873-881.
  • 3Gandhi SK, Ryder DH, Brown N J, Losartan blockers aldosterone and renal vascular responses to angiotensin Ⅱ in humans [J].Hypertension, 1996; 128(6) : 961.
  • 4Anderson WP, Kett, MM, Evans, et al. Pre-glomerular structural changes in the renal vasculature [J].Hypertension Blood Press,1995 ;2(suppl) : 74-80.
  • 5Smith RD,Sweet CS, Goldberg A, et al. Losartan potassium(XozaarTm) : A nonpeptide antagonist of angiotensin Ⅱ [J]. Drugs Today, 1995 ;31(7) : 463-9.
  • 6Mahrour M ,Touyz RM ,Schiffrim EL. Differential ANG Ⅱ -induced growth activation pathways in mesenteric artery muscle cells from SHR [J]. Am Physiol Heart Cire Physiol, 2001 ; 281 (1):H30-39.

同被引文献65

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部